BB Biotech AG Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 3/17/2026)
| Balance Sheet | Total Assets | 2,785,760,000.00 | ROE | 99.75 % |
| Balance Sheet | Total Equity | 2,778,790,000.00 | ROA | 20.75 % |
| Cashflow | Capital Expenditures | -1.00 | P/FCF | 8.70 |
| Cashflow | Free Cash Flow | 309,144,992.00 | – | – |
| Cashflow | Operating Cash Flow | 309,145,000.00 | P/CF | 8.70 |
| Income | Earnings per Share (diluted) | 10.48 | Div. Yield | 4.62 % |
| Income | Net Income | 578,133,000.00 | P/E | 4.65 |
| Income | Shares Outstanding | 55,149,200.00 | P/B | 0.97 |
| Income | Total Revenue | 587,007,000.00 | P/S | 4.58 |
Ratios calculated on: 10/14/2026
Company Description
BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Companys portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.bbbiotech.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more